data

',''); } } ?>

DENVER & NEW YORK–(BUSINESS WIRE)–CoreSite, a leading hybrid IT solutions provider and subsidiary of American Tower Corporation (NYSE: AMT) (“American Tower”) and Stonepeak, a leading alternative investment firm specializing in infrastructure and real assets, today announced that Stonepeak, on behalf of certain affiliated investment vehicles, invested an additional $570.0 million, which, together with its initial $2.5 billion investment in August 2022, on a fully converted basis and based on the currently outstanding equity, represents an approximately 36% ownership interest in American Tower’s U.S. data center business. The conversion is expected to occur four years from the date of the initial closing in August 2022. The upsize transaction was completed on October 20, 2022. The upsize investment comprises both common equity and mandatorily convertible preferred equity, on the same terms and valuation as the initial investment. Stonepeak’s investment is part of its core infrastructure strategy.

J.P. Morgan is serving as lead financial advisor to American Tower, who is also being advised by CDX Advisors. Cleary Gottlieb Steen & Hamilton LLP is serving as principal legal advisor to American Tower, who is also being advised by Sullivan & Worcester LLP with respect to certain REIT and tax matters. MUFG Bank, Ltd. is serving as sole financial advisor to Stonepeak. Sidley Austin LLP is serving as principal legal advisor to Stonepeak.

About CoreSite

CoreSite, an American Tower company (NYSE: AMT), provides hybrid IT solutions that empower enterprises, cloud, network, and IT service providers to monetize and future-proof their digital business. Our highly interconnected data center campuses offer a native digital supply chain featuring direct cloud onramps to enable our customers to build customized hybrid IT infrastructure and accelerate digital transformation. For more than 20 years, CoreSite’s team of technical experts have partnered with customers to optimize operations, elevate customer experience, dynamically scale, and leverage data to gain competitive edge. For more information, visit CoreSite.com and follow us on LinkedIn and Twitter.

About Stonepeak

Stonepeak is a leading alternative investment firm specializing in infrastructure and real assets with approximately $51.7 billion of assets under management. Through its investment in defensive, hard-asset businesses globally, Stonepeak aims to create value for its investors and portfolio companies, and to have a positive impact on the communities in which it operates. Stonepeak sponsors investment vehicles focused on private equity and credit. The firm provides capital, operational support, and committed partnership to sustainably grow investments in its target sectors, which include communications, energy transition, transport and logistics, and social infrastructure. Stonepeak is headquartered in New York with offices in Austin, Hong Kong, Houston, London and Sydney. For more information, please visit www.stonepeak.com.

Cautionary Language Regarding Forward-Looking Statements

This press release contains statements about future events and expectations, or “forward-looking statements,” all of which are inherently uncertain. We have based those forward-looking statements on management’s current expectations and assumptions and not on historical facts. Examples of these statements include, but are not limited to, statements regarding the transaction described above and the value and future investment activities of our U.S. data center business. These forward-looking statements involve a number of risks and uncertainties. For important factors that may cause actual results to differ materially from those indicated in our forward-looking statements, we refer you to the information contained in Item 1A of American Tower’s Form 10-K for the year ended December 31, 2021, as updated in American Tower’s Form 10-Q for the nine months ended September 30, 2022, each under the caption “Risk Factors” and in other filings American Tower makes with the Securities and Exchange Commission. Neither we nor American Tower undertake any obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

Contacts

American Tower
Adam Smith
Senior Vice President, Investor Relations
(617) 375-7500
Investor.Relations@AmericanTower.com

CoreSite
Megan Ruszkowski
Vice President of Marketing
(720) 446-2014
Megan.Ruszkowski@CoreSite.com

Stonepeak
Kate Beers
(646) 540-5225
Beers@Stonepeak.com

The post Stonepeak Upsizes Invesment in American Tower’s Data Center Business appeared first on Web Hosting | Cloud Computing | Datacenter | Domain News.

Read more

Filed under Web Hosting News by on #

  • Football DataCo extends official tracking partnership established with Genius Sports’ Second Spectrum technology in 2019, covering all Premier League matches
  • New agreement includes a sub-second tracking feed and an innovative skeletal tracking partnership with future benefits for fans, media, and broadcast, teams and coaches
  • Genius Sports is the incumbent long-term official betting data and integrity partner to Football DataCo

NEW YORK & LONDON–(BUSINESS WIRE)–Genius Sports Limited (“Genius Sports”) (NYSE:GENI), the official data, technology and broadcast partner that powers the ecosystem connecting sports, betting and media, has clinched an expansion of its Official Tracking Data partnership with Football DataCo (“FDC”), the data rights holder of UK soccer, to capture sub-second and skeletal tracking data across the Premier League (“PL”).

Genius Sports will continue as the Official Tracking Provider of FDC through its Second Spectrum technology. Already installed in every PL ground, Genius Sports’ technology is powered by state-of-the-art computer vision and AI and will now, automatically capture sub-second positional data on every player and the ball.

FDC will also work with Genius Sports to develop and exploit skeletal tracking data for the benefit of the PL, fans, media partners and broadcasters. These new insights will create new opportunities for media partners and power richer fan experiences which could include dynamic, interactive metaverse applications that allow fans to put themselves directly into the action and control how they experience the game.

Global broadcast partners of the PL can access a suite of data-driven augmentation solutions, helping to bring their programs to life with live statistics and metrics including player speeds and shot velocities. PL clubs will also be able to deploy Genius Sports’ advanced Insight feed to enhance performance through rich team and player metrics, integrated with machine-learned video indexing.

Adrian Ford, General Manager of Football DataCo, commented: “Technology continues to drive how data is collected, analyzed and presented. Working with Genius Sports’ Second Spectrum technology enables Football DataCo to be at the cutting edge of what is possible, and we look forward to developing new ways of using data for our stakeholders.”

Mark Locke, CEO of Genius Sports, added “This partnership is an important next step in demonstrating the way data and advanced technology can amplify storytelling and fan engagement. Genius has believed deeply in this vision for many years, which is now becoming a reality in partnership with Football DataCo and the Premier League. We’re incredibly excited to work on solutions to enhance how the most popular league in world soccer is consumed by millions of passionate fans worldwide.”

Genius Sports is also FDC’s exclusive supplier of official live data to the global sports betting sector, providing the fastest, most accurate feed on all competitions organized by the PL, English Football League and Scottish Professional Football League.

About Genius Sports
Genius Sports is the official data, technology and broadcast partner that powers the global ecosystem connecting sports, betting and media. Our technology is used in over 150 countries worldwide, creating highly immersive products that enrich fan experiences for the entire sports industry.

We are the trusted partner to over 400 sports organizations, including many of the world’s largest leagues and federations such as the NFL, EPL, FIBA, NCAA, NASCAR, AFA and Liga MX.

Genius Sports is uniquely positioned through cutting-edge technology, scale and global reach to support our partners. Our innovative use of big data, computer vision, machine learning, and augmented reality, connects the entire sports ecosystem from the rights holder all the way through to the fan.

About Football DataCo
Football DataCo was formed in 2001 by the professional football leagues in England and Scotland to protect, market and commercialise their official match related data.

Working with the Premier League, EFL, SPFL and a series of partners, Football DataCo oversees the collection, management and distribution of the League’s official event and performance data worldwide.

Football DataCo also protects the copyright of Premier League and EFL still action images, and runs the online media accreditation tool for journalists and photographers to apply to attend their matches.

Contacts

Press:
Chris Dougan, Chief Communications Officer
+1 (202) 766-4430
chris.dougan@geniussports.com

Investors:
Brandon Bukstel, Investor Relations Manager
+1 (954)-554-7932
brandon.bukstel@geniussports.com

The post Football DataCo expands official data partnership with Genius Sports to include sub-second, skeletal tracking for the English Premier League appeared first on Web Hosting | Cloud Computing | Datacenter | Domain News.

Read more

Filed under Web Hosting News by on #

Highlights:


  • Delivers data rate of up to 64 GT/s for high-performance workloads
  • Supports the full feature set of PCIe 6.0 with PHY support for CXL 3.0
  • Offers complete IP solution optimized for latency, power, and area
  • Provides cutting-edge security to protect valuable data assets

SAN JOSE, Calif.–(BUSINESS WIRE)–#AIRambus Inc. (NASDAQ: RMBS), a premier chip and silicon IP provider making data faster and safer, today announced the availability of its PCI Express® (PCIe®) 6.0 Interface Subsystem comprised of PHY and controller IP. The Rambus PCIe Express 6.0 PHY also supports the latest version of the Compute Express Link™ (CXL™) specification, version 3.0.

“The rapid advancement of AI/ML and data-intensive workloads is driving the continued evolution of data center architectures requiring ever higher levels of performance,” said Scott Houghton, general manager of Interface IP at Rambus. “The Rambus PCIe 6.0 Interface Subsystem supports the performance requirements of next-generation data centers with premier latency, power, area and security.”

The Rambus PCIe 6.0 Interface Subsystem delivers data rates of up to 64 Gigatransfers per second (GT/s) and has been fully optimized to meet the needs of advanced heterogenous computing architectures. Within the subsystem, the PCIe controller features an Integrity and Data Encryption (IDE) engine dedicated to protecting the PCIe links and the valuable data transferred over them. On the PHY side, full support for CXL 3.0 is available to enable chip-level solutions for cache-coherent memory sharing, expansion and pooling.

“PCIe is ubiquitous in the data center and CXL will become increasingly important as companies pursue ever-escalating speeds and bandwidths to support higher levels of performance in next-generation applications,” said Shane Rau, research vice president, Computing Semiconductors at IDC. “As a growing number of chip companies emerge to support new data center architectures, access to high-performance interface IP solutions will be key to enabling the ecosystem.”

Key features of the Rambus PCIe 6.0 Interface Subsystem include:

  • Supports PCIe 6.0 specification including 64 GT/s data rate and PAM4 signaling
  • Implements low-latency Forward Error Correction (FEC) for link robustness
  • Supports fixed-sized FLITs that enable high-bandwidth efficiency
  • Backward compatible to PCIe 5.0, 4.0 and 3.0/3.1
  • State-of-the-art security with an IDE engine (controller)
  • Supports CXL 3.0 for new use models that optimize memory resources (PHY)

More Information:
For more information on the PCIe 6.0 Interface Subsystem, please visit rambus.com/interface-ip/serdes/pcie6-phy/.

Follow Rambus:
Company website: rambus.com
Rambus blog: rambus.com/blog
Twitter: @rambusinc
LinkedIn: www.linkedin.com/company/rambus
Facebook: www.facebook.com/RambusInc

About Rambus Inc.
Rambus is a provider of industry-leading chips and silicon IP making data faster and safer. With over 30 years of advanced semiconductor experience, we are a pioneer in high-performance memory subsystems that solve the bottleneck between memory and processing for data-intensive systems. Whether in the cloud, at the edge or in your hand, real-time and immersive applications depend on data throughput and integrity. Rambus products and innovations deliver the increased bandwidth, capacity and security required to meet the world’s data needs and drive ever-greater end-user experiences. For more information, visit rambus.com.

Contacts

Cori Pasinetti
Rambus Corporate Communications
t: (650) 309-6226
cpasinetti@rambus.com

The post Rambus Delivers PCIe 6.0 Interface Subsystem for High-Performance Data Center and AI SoCs appeared first on Web Hosting | Cloud Computing | Datacenter | Domain News.

Read more

Filed under Web Hosting News by on #

– Tertiary endpoint data show trends of continuous improvement in activities of daily living, fatigue, and endurance over 24 months

– These data indicate the potential for sustained improvement in quality-of-life measures for patients with symptomatic SMA and offer further evidence of possible durable effects of apitegromab

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced new quality-of-life (QoL) data from its Phase 2 TOPAZ trial extension period evaluating patient outcomes after 24 months of treatment which indicate stabilization or continued improvement with apitegromab for nonambulatory patients with Types 2 and 3 spinal muscular atrophy (SMA) receiving an SMN-targeted therapy. The data were featured in a podium presentation today by Basil Darras, M.D., Associate Neurologist-in-Chief, Boston Children’s Hospital and Professor of Neurology, Harvard Medical School, at the 3rd International Scientific Congress on SMA in Barcelona, Spain (SMA Europe 2022).

“SMA can have a significant impact on the ability to perform daily activities but there is limited research on potential interventions to improve quality-of-life measures, such as increasing muscle endurance and reducing fatigue.1,2 These positive TOPAZ data indicate sustained improvements of quality-of-life measures over 24 months in the patient population studied,” said Jay Backstrom, M.D., M.P.H., Chief Executive Officer of Scholar Rock. “As the Phase 3 SAPPHIRE trial advances, these additional TOPAZ trial analyses coupled with the previously reported measures of motor function, such as HFMSE and RULM, continue to yield positive, consistent results, building the case for apitegromab as a promising new treatment option for patients with SMA.”

The TOPAZ trial assessed activities of daily living (ADL), fatigue, and muscle endurance by three tertiary endpoint measures:

  1. The Pediatric Evaluation of Disability Inventory-Computer Adaptive Test (PEDI-CAT) measures pediatric abilities through three functional domains, daily activities, mobility, and social cognition;3
  2. Patient Reported Outcome Measurement Information System (PROMIS) measures mild subjective feelings of tiredness to debilitating and sustained feelings of exhaustion, with lower scores reflecting less fatigue;4,5 and
  3. Endurance Shuttle Box and Block Test (ESBBT), a muscle endurance measurement tool, evaluates how fast a patient fatigues with the added measure of endurance6 and may be complementary to outcome measures that focus on arm motor function, such as the Revised Upper Limb Module (RULM) assessment.

The tertiary endpoint data from these measures show trends of continuous improvement over 24 months. These data are relevant for informing the therapeutic hypotheses being evaluated in the Phase 3 SAPPHIRE trial. Limitations of these exploratory quality-of-life data analyses include small patient sample sizes in an open-label study, and further exploration is warranted. Specifically, the data found:

  • Nonambulatory Type 2 patients (aged two or older who began receiving nusinersen maintenance therapy before age five) reported stabilization or continuous improvements in ADL up to a mean change from baseline of 3 points (n=14) in PEDI-CAT scores and fatigue up to a mean change from baseline of 5 points (n=10) in PROMIS scores over 24 months of apitegromab.
  • Nonambulatory Types 2 and 3 patients (aged five to 21 who began receiving nusinersen maintenance therapy at or after age five) reported stabilization or increases in ADL up to a mean change from baseline of 0.7 points (n=8) in PEDI-CAT scores, and less fatigue up to a mean change from baseline of 3.5 points (n=2) in PROMIS scores over 24 months of apitegromab. Additionally, these patients also experienced trends in improvements in fatigability and endurance measures based on mean change in ESBBT activities. The trends of improvement with ESBBT are consistent with the previously reported increases in RULM scores observed in the TOPAZ trial at 24 months.

These findings complement previously reported data from the TOPAZ trial 24-month extension period that demonstrated sustained and durable improvements in motor function as measured by the Hammersmith Functional Motor Scale Expanded (HFMSE) and RULM in patients with nonambulatory Types 2 and 3 SMA.

No safety risks were identified over 24 months of treatment. The incidence and severity of adverse events were consistent with the underlying patient population and nusinersen therapy. The five most common treatment-emergent adverse events (TEAEs) were headache, pyrexia, upper respiratory tract infection, cough, and nasopharyngitis. No deaths or serious adverse reactions have been observed with apitegromab. A total of 14 serious TEAEs have been reported over the 24-month treatment period, all assessed by the respective trial investigator as unrelated to apitegromab.

Of the 55 patients who completed the 24-month TOPAZ extension period, 54 have opted to continue treatment in the 36-month extension period.

About the Phase 2 TOPAZ Trial

The TOPAZ trial is an ongoing proof-of-concept, open-label Phase 2 trial evaluating the safety and efficacy of apitegromab in patients with Types 2 and 3 SMA. In the main treatment period, patients were dosed intravenously every four weeks as monotherapy or with nusinersen, an approved SMN therapy. The trial enrolled 58 patients in the U.S. and Europe. The primary efficacy endpoints were mean change from baseline in Revised Hammersmith Scale (RHS) score at 12 months for the ambulatory population (Cohort 1), and mean change from baseline in HFMSE score at 12 months for the nonambulatory population (Cohorts 2 and 3). The trial also includes multiple 12-month extension periods designed to evaluate longer-term patient outcomes.

About Apitegromab

Apitegromab is a selective inhibitor of the activation of myostatin and is an investigational product candidate for the treatment of patients with spinal muscular atrophy (SMA). Myostatin, a member of the TGFβ superfamily of growth factors, is expressed primarily by skeletal muscle cells, and the absence of its gene is associated with an increase in muscle mass and strength in multiple animal species, including humans. Scholar Rock believes that inhibiting myostatin activation with apitegromab may promote a clinically meaningful improvement in motor function in patients with SMA. The U.S. Food and Drug Administration (FDA) has granted Fast Track, Orphan Drug and Rare Pediatric Disease designations, and the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) and Orphan Medicinal Product designations, to apitegromab for the treatment of SMA. The efficacy and safety of apitegromab have not been established and apitegromab has not been approved for any use by the FDA or any other regulatory agency.

About SMA

Spinal muscular atrophy (SMA) is a rare, and often fatal, genetic disorder that typically manifests in young children. An estimated 30,000 to 35,000 patients are afflicted with SMA in the United States and Europe. It is characterized by the loss of motor neurons, atrophy of the voluntary muscles of the limbs and trunk and progressive muscle weakness. The underlying pathology of SMA is caused by insufficient production of the SMN (survival of motor neuron) protein, essential for the survival of motor neurons, and is encoded by two genes, SMN1 and SMN2. While there has been progress in the development of therapeutics that address the underlying SMA genetic defect, via SMN-dependent pathways, there continues to be a high unmet need for therapeutics that directly address muscle function.

About Scholar Rock

Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Scholar Rock is creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. Scholar Rock’s approach to targeting the molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level. By developing product candidates that act in the disease microenvironment, the Company intends to avoid the historical challenges associated with inhibiting growth factors for therapeutic effect. Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient development path. For more information, please visit www.ScholarRock.com or follow Scholar Rock on Twitter (@ScholarRock) and LinkedIn (https://www.linkedin.com/company/scholar-rock/).

Availability of Other Information About Scholar Rock

Investors and others should note that we communicate with our investors and the public using our company website www.scholarrock.com, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on Twitter and LinkedIn. The information that we post on our website or on Twitter or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Scholar Rock® is a registered trademark of Scholar Rock, Inc.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Scholar Rock’s future expectations, plans and prospects, including without limitation, Scholar Rock’s expectations regarding its growth, strategy, progress and timing of its clinical trials for apitegromab, and other product candidates and indication selection and development timing, the ability of any product candidate to perform in humans in a manner consistent with earlier nonclinical, preclinical or clinical trial data, and the potential of its product candidates and proprietary platform. The use of words such as “may,” “might,” “could,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify such forward-looking statements. All such forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, without limitation, that preclinical and clinical data, including the results from the Phase 2 clinical trial, including extension periods, of apitegromab are not predictive of, may be inconsistent with, or more favorable than, data generated from future clinical trials of the same product candidate, including, without limitation, the Phase 3 clinical trial of apitegromab in SMA, Scholar Rock’s ability to provide the financial support, resources and expertise necessary to identify and develop product candidates on the expected timeline, the data generated from Scholar Rock’s nonclinical and preclinical studies and clinical trials, information provided or decisions made by regulatory authorities, competition from third parties that are developing products for similar uses, Scholar Rock’s ability to obtain, maintain and protect its intellectual property, Scholar Rock’s dependence on third parties for development and manufacture of product candidates including, without limitation, to supply any clinical trials, Scholar Rock’s ability to manage expenses and to obtain additional funding when needed to support its business activities and establish and maintain strategic business alliances and new business initiatives, and the impacts of public health pandemics such as COVID-19 on business operations and expectations, as well as those risks more fully discussed in the section entitled “Risk Factors” in Scholar Rock’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, as well as discussions of potential risks, uncertainties, and other important factors in Scholar Rock’s subsequent filings with the Securities and Exchange Commission. Any forward-looking statements represent Scholar Rock’s views only as of today and should not be relied upon as representing its views as of any subsequent date. All information in this press release is as of the date of the release, and Scholar Rock undertakes no duty to update this information unless required by law.

1 Wan HWY, Carey KA, D’Silva A, et al. Orphanet J Rare Dis. 2020;15:70.
2 Yang M. et al. Adv Ther. (2022) 39:1915–1958 https://doi.org/10.1007/s12325-022-02089-2.
3 Cre Care. PEDI-CAT. Accessed April 26, 2022. https://www.pedicat.com/.
4 NIH. PROMIS. Accessed April 26, 2022. https://commonfund.nih.gov/promis/index.
5 Belter L, et al. Orphanet Journal of Rare Diseases. 2020;15:217.
6 Cure SMA. Best Practices for Physical Therapists and Clinical Evaluators in Spinal Muscular Atrophy (SMA). 2021. Available at: https://www.curesma.org/wp-content/uploads/2021/09/Clinical-Evaluators-Best-Practices-13-August-2021.pdf.

Contacts

Scholar Rock:
Investors
Rushmie Nofsinger
Scholar Rock
rnofsinger@scholarrock.com
ir@scholarrock.com
857-259-5573

Media
Ariane Lovell
Finn Partners
ariane.lovell@finnpartners.com
media@scholarrock.com
917-565-2204

The post New Phase 2 TOPAZ Trial Data Indicate Positive Trends in Quality-of-Life Measures Over 24 Months with Apitegromab for Nonambulatory Patients with Types 2 and 3 SMA appeared first on Web Hosting | Cloud Computing | Datacenter | Domain News.

Read more

Filed under Web Hosting News by on #

This support reduces friction of sending logs to New Relic from Amazon Web Services (AWS), allowing customers to quickly understand key insights for performance analytics and troubleshoot network connectivity

SAN FRANCISCO–(BUSINESS WIRE)–#APMNew Relic (NYSE: NEWR), the observability company, announced support for Amazon Virtual Private Cloud (Amazon VPC) Flow Logs on Amazon Kinesis Data Firehose to reduce the friction of sending logs to New Relic. Amazon VPC Flow Logs from AWS is a feature that allows customers to capture information about the IP traffic going to and from network interfaces in their Virtual Private Cloud (VPC). With New Relic support for Amazon VPC Flow Logs, both AWS and New Relic customers can quickly gain a clear understanding of a network’s performance and troubleshoot activity without impacting the network throughput or latency.

Network telemetry is challenging even for network engineers. To unlock cloud-scale observability, engineers need to explore VPC performance and connectivity across multiple accounts and regions to understand if an issue started in the network or somewhere else. To solve this, New Relic has streamlined the delivery of Amazon VPC Flow Logs by allowing engineers to send them to New Relic via Kinesis Data Firehose, which reliably captures, transforms, and delivers streaming data to data lakes, data stores, and analytics services. With New Relic’s simple “add data” interface, it only takes moments to configure Amazon VPC Flow Logs using the AWS Command Line Interface (AWS CLI) or an AWS CloudFormation template. Instead of digging through raw logs across multiple accounts, any engineer can begin with an Amazon Elastic Compute Cloud (Amazon EC2) instance they own and begin to explore the data that matters, regardless of the AWS account or AWS Region.

“New Relic continues to invest in our relationship with AWS. Helping customers gain visibility into their cloud networking environment increases their overall application observability,” said Riya Shanmugam, GVP, Global Alliances and Channels at New Relic. “Our support for Amazon VPC shows our commitment to enhancing our joint customers’ observability experience.”

“AWS is delighted to continue our strategic collaboration with New Relic to help customers innovate and migrate faster to the cloud,” said Nishant Mehta, Director of PM – EC2 and VPC Networking at AWS. “New Relic’s connected experience for Amazon VPC Flow Logs, paired with the simplicity of using Kinesis Data Firehose, enables our joint customers to easily understand how their networks are performing, troubleshoot networking issues more quickly, and explore their VPC resources more readily.”

With the New Relic support for Amazon VPC Flow Logs on Kinesis Data Firehose, customers can:

  • Monitor and alert on network traffic from within New Relic.
  • Visualize network performance metrics such as bytes and packets per second, as well as accepts and rejects per second across every TCP or UDP port.
  • Explore flow log deviations to look for unexpected changes in network volume or health.
  • Diagnose overly restrictive security group rules or potentially malicious traffic issues.

”Our architecture contains above 200 microservices running on AWS. When something goes wrong, we need to find the root cause quickly to put out what we at Gett term as ‘fires,’” said Dani Konstantinovski, Global Support Manager at Gett. “With New Relic capabilities we can identify the problem, understand exactly what services were affected, what’s the reason, and what we need to do to resolve it. New Relic gives us this observability—it helps us to provide better service for our customers.”

“Proactively managing customer experience is essential to all businesses that provide part or all of their services through applications. Therefore it’s essential for engineers to have a clear understanding of their network performance and have the data needed to troubleshoot activity before it impacts customers. Also, the quality of the data is fundamental to making good decisions,” said Stephen Elliot, IDC Group Vice President, I&O, Cloud Operations and DevOps. “Solutions that ensure fast delivery of high-quality data provide engineers with the ability to act quickly and decisively with confidence, saving businesses from the costs associated with negative customer experiences.”

The New Relic support for Amazon VPC Flow Logs on Kinesis Data Firehose is available to all New Relic Full Platform users. For more information, check out our blog post, or visit www.newrelic.com.

About New Relic

As a leader in observability, New Relic empowers engineers with a data-driven approach to planning, building, deploying, and running great software. New Relic delivers the only unified data platform that empowers engineers to get all telemetry—metrics, events, logs, and traces—paired with powerful full stack analysis tools to help engineers do their best work with data, not opinions. Delivered through the industry’s first usage-based consumption pricing that’s intuitive and predictable, New Relic gives engineers more value for the money by helping improve planning cycle times, change failure rates, release frequency, and mean time to resolution. This helps the world’s leading brands including Adidas Runtastic, American Red Cross, Australia Post, Banco Inter, Chegg, GoTo Group, Ryanair, Sainsbury’s, Signify Health, TopGolf, and World Fuel Services (WFS) improve uptime, reliability, and operational efficiency to deliver exceptional customer experiences that fuel innovation and growth. www.newrelic.com.

Forward-looking statements

This press release contains “forward-looking” statements, as that term is defined under the federal securities laws, including but not limited to statements regarding new functions of New Relic platform or products, including any anticipated benefits, results and future opportunities related thereto. The achievement or success of the matters covered by such forward-looking statements are based on New Relic’s current assumptions, expectations, and beliefs and are subject to substantial risks, uncertainties, assumptions, and changes in circumstances that may cause New Relic’s actual results, performance, or achievements to differ materially from those expressed or implied in any forward-looking statement. Further information on factors that could affect New Relic’s financial and other results and the forward-looking statements in this press release is included in the filings New Relic makes with the SEC from time to time, including in New Relic’s most recent Form 10-Q, particularly under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Copies of these documents may be obtained by visiting New Relic’s Investor Relations website at http://ir.newrelic.com or the SEC’s website at www.sec.gov. New Relic assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

Contacts

Media Contact
Francesca DeAnda
New Relic, Inc.
PR@newrelic.com

Investor Contact
New Relic, Inc.
503-336-9280
IR@newrelic.com

The post New Relic Announces Support for Amazon VPC Flow Logs on Amazon Kinesis Data Firehose appeared first on Web Hosting | Cloud Computing | Datacenter | Domain News.

Read more

Filed under Web Hosting News by on #

– Poster presentation at the 2022 Annual Meeting of the European Society of Medical Oncology (ESMO), Paris, France

PALO ALTO, Calif.–(BUSINESS WIRE)–#innovation–Exai Bio, a next-generation liquid biopsy company, and researchers at UCSF are presenting data from a new study in a poster entitled “Serum-based colorectal cancer detection using orphan noncoding RNAs” at the 2022 European Society of Medical Oncology (ESMO) meeting. This case-control study of 191 subjects demonstrated that Exai’s novel, RNA-based platform accurately predicted colorectal cancer (CRC) cases versus non-cancer controls, both overall and across the full ranges of cancer stages and categories of tumor size/extent.

Exai Bio’s technology is based on using cell-free RNA sequencing to identify a novel class of cancer-associated small non-coding RNAs, termed orphan non-coding RNAs (oncRNAs). Exai has created a proprietary library of >250,000 oncRNAs found in several types of cancer. Because oncRNAs can be actively secreted by cancer cells, they are readily detectable in the blood of cancer patients and are largely absent in healthy individuals, making them potentially robust biomarkers with high sensitivity and specificity. These features give the Exai Bio RNA-based platform — which uses artificial intelligence (AI) to identify cancer-specific patterns among thousands of oncRNAs — several scientific and practical advantages over tests that use circulating tumor-derived DNA in mutational, epigenomic, or fragmentomic analyses.

In the present poster, the Exai oncRNA-based model, which used machine learning, predicted CRC with a high overall sensitivity of 90.6% at 90% specificity. Predictions were also accurate for stage I cancer (92% sensitivity) and for the lowest categories of tumor size/extent, T1/T2 (92.3% sensitivity), indicating that even the earliest stage cancers and smallest tumors were detectable. Exai Bio is thus positioned to improve patient care by developing a variety of liquid biopsy blood tests for CRC, including for early detection and monitoring of residual disease or recurrence.

Patrick Arensdorf, Chief Executive Officer of Exai Bio, commented, “We are truly excited about these findings. Exai Bio is working to fulfill unmet needs that exist despite recent advances in liquid biopsy testing. This work demonstrates that Exai Bio can measure novel biomarkers in blood-derived samples to accurately predict colorectal cancer, including the earliest-stage and smallest tumors. By achieving greater than 90% sensitivity at 90% specificity, we exceeded the sensitivity hurdle in the published CMS National Coverage Determination for blood-based biomarker tests in CRC screening1. Moreover, the oncRNA-based liquid biopsy technology will be compatible with standard sample requirements enabling easy integration into conventional clinical workflows. These results build on our earlier study in breast cancer and validate the applicability of cell-free RNA methods in yet another tumor type.”

  1. NCD for Colorectal Cancer Screening Test (210.3). Medicare Coverage Decision database: Screening for Colorectal Cancer biomarker-based test: CAG-00454N decision memo 01/19/2021; cms.gov.

Details of the ESMO 2022 eposter presentation:
Title: Serum-based colorectal cancer detection using orphan noncoding RNAs
Abstract category: Biomarkers (agnostic)
Abstract number: 4635
Authors: Hani Goodarzi, Jeffrey Wang, Oluwadamilare I. Afolabi, Lisa Fish, Helen Li, Kimberly H. Chau, Patrick Arensdorf, Fereydoun Hormozdiari, Babak Alipanahi

Posters will be available on-demand on the EMSO website for attendees (www.emso.org) beginning at 12:00 PM CEST on Friday, September 9, 2022 until Tuesday, September 13, 2022 Upon release at ESMO, the poster will be accessible on the publications page of the Exai Bio website.

About Exai Bio

Exai Bio is a next-generation liquid biopsy company. Its mission is to enable a world where cancer can be detected early, diagnosed accurately, treated in a personalized and targeted way, and ultimately cured. The company’s proprietary RNA and artificial intelligence-based liquid biopsy technology delivers clinical insights into cancer biology to enable the earliest, most accurate diagnosis of cancer.

Contacts

For more information: info@exai.bio

The post Exai Bio Presents Data Demonstrating that its Novel RNA-based Liquid Biopsy Platform has Potential for Early Detection and Monitoring of Colorectal Cancer appeared first on Web Hosting | Cloud Computing | Datacenter | Domain News.

Read more

Filed under Web Hosting News by on #